Status:
COMPLETED
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Lead Sponsor:
MedImmune LLC
Conditions:
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Eligibility:
FEMALE
18-99 years
Phase:
PHASE2
Brief Summary
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
Detailed Description
This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-ne...
Eligibility Criteria
Inclusion
- Histologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapy
- Tumors are positive for ER, PgR, or both
- Tumors must be negative for HER2 (by FISH, CISH or IHC)
- Female gender and age ≥ 18 years at time of study entry
- Postmenopausal
- Karnofsky Performance Status ≥ 70
- Life expectancy of ≥ 6 months
Exclusion
- Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic therapy for advanced or metastatic disease with the following exceptions:
- Prior adjuvant therapy with an AI and/or tamoxifen is allowed, provided treatment ended at least 2 weeks prior to the first dose of MEDI-573
- Prior neoadjuvant and/or adjuvant chemotherapy for breast cancer is allowed
- Extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or disease that is considered by the investigator to be rapidly progressing or life threatening (eg, subjects who are intended for chemotherapy)
- Active brain metastases with the exception of subject has been treated and are asymptomatic and there has been no evidence of CNS progression for at least 4 weeks of first dose of MEDI-573
- Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis
- Unresolved toxicities from prior therapy with the exception of alopecia that have not resolved to ≤ Grade 1 at the time of starting study treatment
- Previous treatment with agents that target the IGF receptor
- History of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI-573 or AI
- History of another invasive malignancy within 5 years except for curatively resected nonmelanoma skin cancer or carcinoma in situ of the cervix
- Poorly controlled diabetes mellitus
Key Trial Info
Start Date :
June 13 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2019
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT01446159
Start Date
June 13 2011
End Date
June 28 2019
Last Update
June 2 2020
Active Locations (71)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85259
2
Research Site
Bakersfield, California, United States, 93309
3
Research Site
Pleasant Hill, California, United States, 94523
4
Research Site
Stamford, Connecticut, United States, 06904